NASDAQ:BVXV

BiondVax Pharmaceuticals (BVXV) Stock Forecast, Price & News

$1.50

-0.03 (-1.96%)

(As of 02:36 PM ET)

Compare

Today's Range: $1.31
▼
$1.57
50-Day Range: $1.53
▼
$2.16
52-Week Range: $1.31
▼
$13.50

Volume: 338,098 shs
Average Volume: 184,333 shs
Market Capitalization: $2.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About BiondVax Pharmaceuticals (NASDAQ:BVXV) Stock

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Stock News Headlines

June 6, 2023 | americanbankingnews.com

BiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated at StockNews.com

June 5, 2023 | finance.yahoo.com

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

June 6, 2023 | Edge On The Street (Ad)

Soaring EV Industry Keeps Investor Focus on Lithium

The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.

June 3, 2023 | americanbankingnews.com

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Expected to Earn FY2023 Earnings of ($0.01) Per Share

May 31, 2023 | americanbankingnews.com

Brokers Issue Forecasts for BiondVax Pharmaceuticals Ltd.'s Q2 2023 Earnings (NASDAQ:BVXV)

May 30, 2023 | finance.yahoo.com

BVXV: Developing anti-IL-17 NanoAb

May 28, 2023 | americanbankingnews.com

BiondVax Pharmaceuticals (NASDAQ:BVXV) Receives New Coverage from Analysts at StockNews.com

May 21, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on BiondVax Pharmaceuticals (NASDAQ:BVXV)

June 6, 2023 | Edge On The Street (Ad)

Is There Still Time to Get In On the Lithium Boom?

"Lithium demand from the electric vehicle (EV) industry is growing at twice the rate of lithium production. By 2030, experts predict that 26 million EVs will be on U.S. roads, up from around 600,000 today. That's why new government incentives have been put in place to support more urgently-needed "Made in America" lithium.

May 15, 2023 | finanznachrichten.de

BiondVax Pharmaceuticals Ltd.: BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023 | msn.com

Biondvax Pharmaceuticals GAAP EPS of $0.00 beats by $0.73

May 15, 2023 | finance.yahoo.com

BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update

April 26, 2023 | americanbankingnews.com

BiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by Analysts at StockNews.com

April 20, 2023 | theglobeandmail.com

BiondVax Pharmaceuticals (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team

April 18, 2023 | finanznachrichten.de

BiondVax Pharmaceuticals Ltd.: BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

April 4, 2023 | marketwatch.com

BioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies

March 26, 2023 | marketwatch.com

BioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants

March 25, 2023 | americanbankingnews.com

BiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated by Analysts at StockNews.com

March 16, 2023 | finance.yahoo.com

BiondVax to Present at BIO-Europe Spring

March 6, 2023 | finance.yahoo.com

IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman

March 3, 2023 | finance.yahoo.com

IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes

February 2, 2023 | finance.yahoo.com

BiondVax Presenting at BIO CEO & Investor Conference

January 25, 2023 | benzinga.com

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study

January 25, 2023 | benzinga.com

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19

January 23, 2023 | markets.businessinsider.com

BiondVax Pharma: In Vivo Data Shows NanoAb Virtually Prevents COVID-19 In Hamsters

January 23, 2023 | finance.yahoo.com

BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate

January 23, 2023 | it.tmcnet.com

BiondVax's Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

See More Headlines

BVXV Price History

30 days | 90 days | 365 days | Advanced Chart

BVXV Company Calendar

Last Earnings: 4/17/2023
Today: 6/06/2023
Next Earnings (Estimated): 8/24/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BVXV
CUSIP: N/A
CIK: 1611747
Web: www.biondvax.com
Phone: 9723029302529
Fax: 972-8930-2531
Employees: 15
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.54)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,800,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -346.36%
Return on Assets: -28.48%

Debt

Debt-to-Equity Ratio: 5.92
Current Ratio: 4.28
Quick Ratio: 4.28

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.94) per share
Price / Book: -1.60

Miscellaneous

Outstanding Shares: 1,870,000
Free Float: 1,755,000
Market Cap: $2.81 million
Optionable: Not Optionable
Beta: 2.47

Key Executives

Amir Reichman
Chief Executive Officer & Director

Elad Mark
Chief Operating Officer

Uri Ben-Or
Chief Financial Officer

Tamar Ben-Yedidia
Chief Science Officer

Dalit Weinstein Fischer
Head-Technical, Research & Development

Key Competitors

View All Competitors

Institutional Ownership

Sabby Management LLC
Bought 105,412 shares on 5/16/2023
Ownership: 17.450%

View All Institutional Transactions

BVXV Stock - Frequently Asked Questions

How have BVXV shares performed in 2023?: BiondVax Pharmaceuticals' stock was trading at $2.96 at the beginning of the year. Since then, BVXV stock has decreased by 49.3% and is now trading at $1.50.
View the best growth stocks for 2023 here.
Are investors shorting BiondVax Pharmaceuticals?: BiondVax Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 18,000 shares, an increase of 20.8% from the April 30th total of 14,900 shares. Based on an average daily trading volume, of 27,000 shares, the days-to-cover ratio is currently 0.7 days.
View BiondVax Pharmaceuticals' Short Interest.
When is BiondVax Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 24th 2023.
View our BVXV earnings forecast.
How were BiondVax Pharmaceuticals' earnings last quarter?: BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) released its quarterly earnings results on Monday, April, 17th. The company reported ($0.30) earnings per share for the quarter.
When did BiondVax Pharmaceuticals' stock split?: BiondVax Pharmaceuticals's stock reverse split on Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of BiondVax Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?: (BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.
What is BiondVax Pharmaceuticals' stock symbol?: BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."
Who are BiondVax Pharmaceuticals' major shareholders?: BiondVax Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (17.45%).
How do I buy shares of BiondVax Pharmaceuticals?: Shares of BVXV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BiondVax Pharmaceuticals' stock price today?: One share of BVXV stock can currently be purchased for approximately $1.50.
How much money does BiondVax Pharmaceuticals make?: BiondVax Pharmaceuticals (NASDAQ:BVXV) has a market capitalization of $2.81 million. The company earns $-5,800,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis.
How can I contact BiondVax Pharmaceuticals?: BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The official website for the company is www.biondvax.com. The company can be reached via phone at 9723029302529, via email at j.phillipson@biondvax.com, or via fax at 972-8930-2531.

This page (NASDAQ:BVXV) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial